Maharaja Agrasen Hospital is a hospital in New Delhi, India with 400 beds. It is located in West Punjabi Bagh. The hospital is named after Maharaja Agrasen, a king of Agroha.

During the past decade, Maharaja Agrasen Hospital conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 1 clinical trials were completed, i.e. on average, 14.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Maharaja Agrasen Hospital" #1 sponsor was "Galapagos NV" with 2 trials, followed by "Eli Lilly and Company" with 1 trials sponsored, "Gilead Sciences" with 1 trials sponsored, "Kowa Research Institute, Inc." with 1 trials sponsored and "Novalead Pharma Private Limited" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Maharaja Agrasen Hospital" #1 collaborator was "Gilead Sciences" with 2 trials as a collaborator and "Brigham and Women's Hospital" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Maharaja Agrasen Hospital" are "Atopic Dermatitis" (1 trials), "Crohn's Disease" (1 trials), "Diabetic Foot Ulcer" (1 trials), "Dyslipidemia" (1 trials) and "Nonalcoholic Steatohepatitis" (1 trials). Many other conditions were trialed in "Maharaja Agrasen Hospital" in a lesser frequency.

Most popular intervention types in "Maharaja Agrasen Hospital" are "Drug" (7 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Filgotinib" (2 trials), "Placebo to match filgotinib" (2 trials), "Abrocitinib 100 mg" (1 trials), "Abrocitinib 200 mg" (1 trials) and "Esmolol Hydrochloride" (1 trials). Other intervention names were less common.

The vast majority of trials in "Maharaja Agrasen Hospital" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Maharaja Agrasen Hospital". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Maharaja Agrasen Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Maharaja Agrasen Hospital, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".